Background Debate over the viability of the current commercial research and development
(R&D) model is ongoing. A controversial theme is the cost of bringing a new molecular entity …

Importance The increasing cost of prescription drugs in the United States has become a
source of concern for patients, prescribers, payers, and policy makers. Objectives To review …

Globally, annual spending on anticancer drugs is around US $100 billion, and is predicted
to rise to $150 billion by 2020. In the USA, a novel anticancer drug routinely costs more than …

Increasing cancer drug prices present global challenges to treatment access and cancer
outcomes. Substantial variability exists in drug pricing across countries. In countries without …

Globally, cancer is the second leading cause of death, with numbers greatly exceeding
those for human immunodeficiency virus/acquired immunodeficiency syndrome …

Nowadays, customer's demands for E-commerce are more diversified, which introduces
more complications to the product retrieval industry. Previous methods are either subject to …

This article discusses pharmaceutical pricing and reimbursement policies in European
countries with regard to their ability to ensure affordable access to medicines. A frequently …

Objectives: The aim of this study is to conduct an analysis on the regulation and application
of managed entry agreements (MEA) for oncology drugs across different European …

In the context of pharmaceutical care, policy-makers repeatedly face the challenge of
balancing patient access to effective medicines with affordability and rising costs. With the …

Background The management of cancer is predicated on the availability and affordability of
anticancer therapies, which may be either curative or noncurative. Aim The primary aims of …